| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$15.9M | ROE | −123.51% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $29.4M | Trading Days | 1359 |
| 52W High | 5.74 |
| 52W Low | 1.11 |
| % Off High | −54.74% |
| YTD | −14.19% | 1Y | −35.16% |
| 3Y | −43.22% | 5Y | −79.86% |
| Since incept. (ann.) | −30.30% |
| Ann. Volatility (1Y) | 99.76% | Ann. Volatility (3Y) | 97.77% |
| Sharpe (1Y) | 0.10 | Sharpe (3Y) | 0.31 |
| Max Drawdown (1Y) | −78.95% | Max Drawdown (3Y) | −89.48% |
| Beta (3Y, vs SPY) | 5.15 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| FBLG | FibroBiologics, Inc. | $29.0M | — |
| BCTX | BriaCell Therapeutics Corp. | $30.2M | — |
| KYNB | KYNTRA BIO, INC. | $28.2M | 0.2 |
| SER | Serina Therapeutics, Inc. | $31.0M | — |
| ABVC | ABVC BIOPHARMA, INC. | $27.6M | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $27.2M | — |
| LITS | Lite Strategy, Inc. | $33.0M | — |
| BTAI | BioXcel Therapeutics, Inc. | $26.1M | — |
| IGC | IGC Pharma, Inc. | $25.9M | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $25.4M | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $25.2M |
| — |
| NNVC | NANOVIRICIDES, INC. | $34.9M | — |
